Home › Funds › Graham Capital Management, L.P. › BBIO

Graham Capital Management, L.P. position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Graham Capital Management, L.P. reported holding 22,241,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$34.6M, representing 1.15% of its reported portfolio and ranking #12 among its reported holdings. Graham Capital Management, L.P. has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)22.24M sh
Reported value held$34.59M
Portfolio Weight1.15%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Graham Capital Management, L.P.'s BBIO position evolved

Graham Capital Management, L.P. first disclosed a stake in BBIO in Q3 2023 at 55,529,000 shares (US$53.5M). The position peaked in Q1 2025 at 55,741,000 shares, worth US$63.6M. Across 13 filings, Graham Capital Management, L.P. increased the stake 5 time(s), trimmed it 5 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 22,241,000 shares valued at US$34.6M. Notable position changes include a 35776% increase in Q1 2024 (shares fell 18% over the following quarter), a 1179604% increase in Q1 2025 (shares rose 25% over the following quarter), a 21910% increase in Q1 2026 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 55.53M $53.48M New
Q4 2023 1.08K $43.56K Reduce
Q1 2024 387.10K $11.97M Add
Q2 2024 16.71K $423.24K Reduce
Q3 2024 32.42K $825.44K Add
Q4 2024 4.72K $129.65K Reduce
Q1 2025 55.74M $63.65M Add
Q2 2025 24.86K $1.07M Reduce
Q3 2025 278.13K $14.45M Add
Q4 2025 101.05K $7.73M Reduce
Q1 2026 22.24M $40.12M Add
Q2 2026 22.24M $39.65M Hold
Q3 2026 22.24M $34.59M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 42 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$937.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Graham Capital Management, L.P. held BBIO?

Graham Capital Management, L.P. has disclosed BBIO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Graham Capital Management, L.P.'s current position in BBIO?

As of Q3 2026, Graham Capital Management, L.P. holds 22.24M shares of BBIO (BRIDGEBIO PHARMA INC), valued at $34.59M, representing 1.15% of its reported portfolio and ranking #12.

Has Graham Capital Management, L.P. been buying or selling BBIO?

In the latest 13F filing (Q3 2026), Graham Capital Management, L.P. held unchanged its position in BBIO. The position peaked in Q1 2025 at 55.74M shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, FARALLON CAPITAL MANAGEMENT, L.L.C., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.